Methods of treating psychosis and schizophrenia based on polymorphisms in the CNTF gene

• US 8,460,867 B2
• Filed: 06/03/2009
• Issued: 06/11/2013
• Est. Priority Date: 12/10/2001
• Status: Expired due to Term

• Current Assignee: Novartis Ag
• Original Assignee: Novartis Ag
• Inventors: Kudaravalli, Sridhar, Polymeropoulos, Mihael Hristos
• Primary Examiner(s): GOLDBERG, JEANINE ANNE
• Application Number:
  US12/477,469
• Publication Number:
  US 20090239908A1
• Time in Patent Office: 1,469 Days
• Field of Search: None
• US Class Current: 435/6.1
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 2333/475 Assays involving growth factors
• CPC Class Codes: G01N 2800/302 Schizophrenia
• CPC Class Codes: G01N 33/6896 Neurological disorders, e.g. Alzheimer's disease

Abstract

This invention relates to the use of the association between the 103 G>A polymorphism in the CNTF gene to determine antipsychotic treatment strategies in patients with psychotic disorders.

Claims

1. A method of treating a psychotic disorder in a human individual in need of such treatment comprising:

a) determining, in a biological sample, for each of the two copies of the CNTF gene present in the individual the identity of the nucleotide pair at the polymorphic site 103G>

A in GenBank sequence reference No. X55890 (Version

     1),

b) detecting the presence of GG at position 103 of the human individual and

c) treating the individual with GG at position 103 with iloperidone.

2. A method according to claim 1, wherein determining includes use of a kit for the identification of the individual'"'"'s polymorphism pattern at the CNTF polymorphic site at 103 G>

A, the kit comprising a means for determining a genetic polymorphism pattern at the CNTF polymorphic site at 103 G>

A.

3. A method according to claim 1, wherein the method is performed ex vivo.

4. A method of treating a psychotic disorder in a human individual in need of such treatment comprising:

a) determining, in a biological sample, the level of mRNA of the CNTF gene wherein the CNTF gene is GenBank sequence reference No. X55890 (Version

     1),

b) comparing the level mRNA determined in the biological sample, to a value of mRNA levels corresponding to a GG at position 103 of the CNTF gene

c) determining the human individual is GG at position 103 and

d) treating the individual with GG at position 103 with iloperidone.

5. A method according to claim 4, wherein detecting includes use of a kit for the identification of an mRNA expression product of the CNTF gene, the kit comprising a means for determining the mRNA expression product of the CNTF gene.